TherapeuticsMD, Inc. Adjustments to Additional Paid in Capital, Other
TherapeuticsMD, Inc. (TXMD) reported Adjustments to Additional Paid in Capital, Other of $370.45 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-12.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2016-02-26
- TherapeuticsMD, Inc. adjustments to additional paid in capital, other for fiscal 2014 was $370.45K, a 57.28% decline from fiscal 2013.
- TherapeuticsMD, Inc. adjustments to additional paid in capital, other for fiscal 2013 was $867.26K.
- TherapeuticsMD, Inc. adjustments to additional paid in capital, other for fiscal 2012 was -$7.83K.
| Period end | Adjustments to Additional Paid in Capital, Other 12 month | Adjustments to Additional Paid in Capital, Other 12 month as first filed |
|---|---|---|
| 2014-12-31 | $370.45K 10-K · filed 2015-03-12 | |
| 2013-12-31 | $867.26K 10-K · filed 2016-02-26 | $83.13K 10-K · filed 2015-03-12 |
| 2012-12-31 | -$7.83K 10-K · filed 2014-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |